Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Profit After Tax (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Profit After Tax for 10 consecutive years, with -$5.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax rose 4.55% to -$5.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$58.9 million, a 101.38% decrease, with the full-year FY2024 number at -$62.9 million, down 299.71% from a year prior.
  • Profit After Tax was -$5.6 million for Q3 2025 at Rein Therapeutics, up from -$6.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$1.8 million in Q2 2023 to a low of -$41.0 million in Q4 2024.
  • A 5-year average of -$7.9 million and a median of -$6.7 million in 2021 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: surged 77.64% in 2023, then crashed 458.4% in 2024.
  • Rein Therapeutics' Profit After Tax stood at -$6.8 million in 2021, then skyrocketed by 33.12% to -$4.5 million in 2022, then crashed by 61.4% to -$7.3 million in 2023, then plummeted by 458.4% to -$41.0 million in 2024, then skyrocketed by 86.38% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Profit After Tax are -$5.6 million (Q3 2025), -$6.8 million (Q2 2025), and -$5.5 million (Q1 2025).